Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

PSMA-PET molecular imaging more often triggers changes in salvage radiation treatment compared with usual care. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging ...

Study findings have implications for biopsy-free radical prostatectomy. Combining PSMA-PET and mpMRI results to diagnose clinically significant prostate cancer while excluding benign prostatic ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

Detection of prostate cancer and its recurrence is challenging as it is a heterogeneous disease and methods such as PET imaging and measurement of biochemical response using prostate specific membrane ...

The FDA has approved flotufolastat F 18 injection for positron emission tomography of prostate-specific membrane antigen–positive lesions in certain men with prostate cancer. The FDA has approved ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window MRI combined ...

MILAN — When added to prostate biopsy, gallium-68 prostate-specific membrane antigen (PSMA)-PET/CT improves detection of clinically significant prostate tumors and helps guide treatment planning, new ...

Today, the U.S. Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) - the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) ...

New PSMA PET/CT can detect signs of prostate cancer within elderly patients without the need of a biopsy. PSMA PET/CT scans can detect signs of prostate cancer in elderly patients without the need of ...

Reston, VA—In men recently diagnosed with intermediate or high-grade prostate cancer, prostate specific membrane antigen (PSMA) PET/MRI can successfully determine whether their cancer is likely to ...

The speed with which PSMA PET–CT has been adopted for prostate cancer imaging is unprecedented. This technique's clinical value in recurrent disease is uncontested, but its role in initial staging is ...